Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105008 | 0.75 | ROCK2 (0.65) | ROCK2ROCK1 | |
| SCHEMBL16457017 | 0.75 | ROCK2 (0.65) | ROCK2ROCK1 | |
| SCHEMBL23453149 | 0.70 | ROCK2 (0.54) | ROCK2ROCK1 | |
| SCHEMBL2775983 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL19886623 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL21194004 | 0.69 | PNMT (0.62) | ROCK2MEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL27865909 | 0.69 | PNMT (0.62) | ROCK2MEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL3336636 | 0.67 | F9 (0.43) | ROCK2ROCK1ALDH1A1 | |
| SCHEMBL21656352 | 0.67 | PNMT (0.56) | ROCK2MEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL1105175 | 0.67 | ROCK2 (0.46) | ROCK2ROCK1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963432-B2 | Beta-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20180050990-A1 | BETA-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050990-A1 | BETA-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, BCAT2, BCAT1 | ROCK2 129/4885ROCK1 223/4885MEN1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.